La Alamedilla Health center
Welcome,         Profile    Billing    Logout  
 18 Trials 
36 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Jose F
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
NCT05397600: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Completed
3
684
Canada, US, RoW
Bimatoprost Ophthalmic
Laboratoires Thea
Glaucoma, Ocular Hypertension
03/24
03/24
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
NCT06075537: An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Enrolling by invitation
2/3
99
Europe, Canada, US, RoW
tividenofusp alfa
Denali Therapeutics Inc.
Mucopolysaccharidosis II
06/27
06/27
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients with NET

Completed
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
10/24
10/24
SAP-001-202, NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Active, not recruiting
2
87
US
SAP-001, Xanthine Oxidase Inhibitor, Colchicine
Shanton Pharma Pte. Ltd.
Gout
01/25
02/25
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Active, not recruiting
2
219
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
01/25
06/25
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 As a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/25
12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 As a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Terminated
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
02/25
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
NCT04812262: A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Completed
1
255
US
DD01, Placebo
Neuraly, Inc.
Overweight and Obesity, Type2 Diabetes, NAFLD
12/22
02/23
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
NCT05332717: TKA Melatonin and Sleep Quality

Completed
N/A
176
US
Melatonin 5 mg, Placebo (Vitamin C)
Hospital for Special Surgery, New York
Arthroplasty, Replacement, Knee, Sleep Initiation and Maintenance Disorders
01/22
04/22
NCT05520593: Preoperative Oral Hydration in the Ambulatory Arthroplasty Population

Recruiting
N/A
312
US
Complex Carbohydrate Drink
Hospital for Special Surgery, New York
Same-day Discharge, Length of Stay
01/26
01/26
Y90-PET-CT, NCT06123676: Introduction of Post Radioembolisation Therapy Scans

Recruiting
N/A
10
Europe
Y90-PET-CT scan, Y90-PET-CT protocol post-therapy scan for patients undergoing 90Y-microspheres or 90Y-radioembolization treatment or SIRT at the Christie NHS Hospital
The Christie NHS Foundation Trust
Cancer
05/26
05/26
NCT07010640: A Comparison of Video Versus Written Instructions for Early Motion Flexors Rehabilitation

Not yet recruiting
N/A
60
US
Video Instrctions
University of Puerto Rico
Compliance, Treatment, Hand Flexor Repair, Compliance to Rehabilitation After Hand Flexor Repair
07/26
07/26
STAR-GLOBAL, NCT04524416: MINIject Global Long-Term Follow-up Study

Recruiting
N/A
300
Europe, RoW
Minimally invasive glaucoma surgery (MIGS)
iSTAR Medical
Open Angle Glaucoma, Ocular Hypertension
12/25
12/25
Alonso, Maria del Mar
advance NEXT, NCT06544499: A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Recruiting
3
63
Europe, US
Efgartigimod IV, Placebo IV
argenx
Primary Immune Thrombocytopenia (ITP)
06/28
06/28
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting
3
733
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
07/29
07/29
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease

Active, not recruiting
N/A
12000
Europe, US
Low-dose CT scan
Guardant Health, Inc.
Lung Cancer
12/25
12/25
Rodríguez, José Manuel Ramírez
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
SPRING, NCT03234023: Secondary PRevention in Cardiovascular Disease by a Nursing Guided Program

Completed
N/A
484
Europe
INTERVENTION GROUP
University Hospital A Coruña
Acute Coronary Syndrome, Nutrition, Physical Activity, Secondary Prevention
02/23
02/23
NCT06134999: Study of Patients With Knee Prostheses Treated With Noninvasive Neuromodulation

Recruiting
N/A
40
Europe
Non-invasive Neuromodulation, Placebo Non-invasive Neuromodulation
University of Las Palmas de Gran Canaria
Knee Prosthesis
05/25
09/25
Dermatitis, NCT05078294: Results in Real Clinical Practice of Treatment of Moderate-severe Atopic

Recruiting
N/A
300
Europe
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Dermatitis, Atopic
06/24
11/24
NCT02832245: Computerized Registry of Patients With Venous Thromboembolism (RIETE)

Recruiting
N/A
120000
Europe, Japan, US, RoW
Manuel Monreal
Venous Thromboembolism
12/26
12/27
Fernández, José A Maderuelo
DapaTAVI, NCT04696185: Dapagliflozin After Transcatheter Aortic Valve Implantation

Completed
4
1257
Europe
Dapagliflozin 10 MG
Spanish Society of Cardiology, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Aortic Stenosis, Transcatether Aortic Valve Implantation
12/24
12/24
Dry002-FiH, NCT06645509: Severe Primary Hand Hyperhidrosis Treatment With Topical Administration of Victorhy

Recruiting
2
60
Europe
TTB gel (dose 1), Victorhy, TTB gel (dose 2), Placebo
Dryox Health
Palmar Hyperhidrosis
06/24
12/24
MISC-SA/T, NCT06150313: Efficacy of the Mediational Intervention for Sensitizing Caregivers for Teachers and Self-Administered Versions

Recruiting
N/A
105
Europe
Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T), MISC for Trainers adapted for groups of Teachers, MISC-T, Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA), MISC-SA, Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU), MISC-R, TAU
Universitat Autonoma de Barcelona, Ministerio de Economía y Competitividad, Spain
Randomized Controlled Trial
01/25
02/25
COPERNICAN, NCT06353594: Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

Recruiting
N/A
1272
Europe
Primary PCI
Jorge Sanz Sanchez
ST Elevation Myocardial Infarction
09/26
09/35
NAGOMI COMPLEX, NCT05705973: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Active, not recruiting
N/A
3000
Europe, RoW
Ultimaster Nagomi™
Terumo Europe N.V.
Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
04/26
04/27
Sánchez, Emiliano Rodríguez
No trials found
Marcos, Manuel A Gomez
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Jose F
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
NCT05397600: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Completed
3
684
Canada, US, RoW
Bimatoprost Ophthalmic
Laboratoires Thea
Glaucoma, Ocular Hypertension
03/24
03/24
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
NCT06075537: An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Enrolling by invitation
2/3
99
Europe, Canada, US, RoW
tividenofusp alfa
Denali Therapeutics Inc.
Mucopolysaccharidosis II
06/27
06/27
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients with NET

Completed
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
10/24
10/24
SAP-001-202, NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Active, not recruiting
2
87
US
SAP-001, Xanthine Oxidase Inhibitor, Colchicine
Shanton Pharma Pte. Ltd.
Gout
01/25
02/25
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Active, not recruiting
2
219
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
01/25
06/25
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 As a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/25
12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 As a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Terminated
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
02/25
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
NCT04812262: A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Completed
1
255
US
DD01, Placebo
Neuraly, Inc.
Overweight and Obesity, Type2 Diabetes, NAFLD
12/22
02/23
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
NCT05332717: TKA Melatonin and Sleep Quality

Completed
N/A
176
US
Melatonin 5 mg, Placebo (Vitamin C)
Hospital for Special Surgery, New York
Arthroplasty, Replacement, Knee, Sleep Initiation and Maintenance Disorders
01/22
04/22
NCT05520593: Preoperative Oral Hydration in the Ambulatory Arthroplasty Population

Recruiting
N/A
312
US
Complex Carbohydrate Drink
Hospital for Special Surgery, New York
Same-day Discharge, Length of Stay
01/26
01/26
Y90-PET-CT, NCT06123676: Introduction of Post Radioembolisation Therapy Scans

Recruiting
N/A
10
Europe
Y90-PET-CT scan, Y90-PET-CT protocol post-therapy scan for patients undergoing 90Y-microspheres or 90Y-radioembolization treatment or SIRT at the Christie NHS Hospital
The Christie NHS Foundation Trust
Cancer
05/26
05/26
NCT07010640: A Comparison of Video Versus Written Instructions for Early Motion Flexors Rehabilitation

Not yet recruiting
N/A
60
US
Video Instrctions
University of Puerto Rico
Compliance, Treatment, Hand Flexor Repair, Compliance to Rehabilitation After Hand Flexor Repair
07/26
07/26
STAR-GLOBAL, NCT04524416: MINIject Global Long-Term Follow-up Study

Recruiting
N/A
300
Europe, RoW
Minimally invasive glaucoma surgery (MIGS)
iSTAR Medical
Open Angle Glaucoma, Ocular Hypertension
12/25
12/25
Alonso, Maria del Mar
advance NEXT, NCT06544499: A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Recruiting
3
63
Europe, US
Efgartigimod IV, Placebo IV
argenx
Primary Immune Thrombocytopenia (ITP)
06/28
06/28
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting
3
733
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
07/29
07/29
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease

Active, not recruiting
N/A
12000
Europe, US
Low-dose CT scan
Guardant Health, Inc.
Lung Cancer
12/25
12/25
Rodríguez, José Manuel Ramírez
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
SPRING, NCT03234023: Secondary PRevention in Cardiovascular Disease by a Nursing Guided Program

Completed
N/A
484
Europe
INTERVENTION GROUP
University Hospital A Coruña
Acute Coronary Syndrome, Nutrition, Physical Activity, Secondary Prevention
02/23
02/23
NCT06134999: Study of Patients With Knee Prostheses Treated With Noninvasive Neuromodulation

Recruiting
N/A
40
Europe
Non-invasive Neuromodulation, Placebo Non-invasive Neuromodulation
University of Las Palmas de Gran Canaria
Knee Prosthesis
05/25
09/25
Dermatitis, NCT05078294: Results in Real Clinical Practice of Treatment of Moderate-severe Atopic

Recruiting
N/A
300
Europe
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Dermatitis, Atopic
06/24
11/24
NCT02832245: Computerized Registry of Patients With Venous Thromboembolism (RIETE)

Recruiting
N/A
120000
Europe, Japan, US, RoW
Manuel Monreal
Venous Thromboembolism
12/26
12/27
Fernández, José A Maderuelo
DapaTAVI, NCT04696185: Dapagliflozin After Transcatheter Aortic Valve Implantation

Completed
4
1257
Europe
Dapagliflozin 10 MG
Spanish Society of Cardiology, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Aortic Stenosis, Transcatether Aortic Valve Implantation
12/24
12/24
Dry002-FiH, NCT06645509: Severe Primary Hand Hyperhidrosis Treatment With Topical Administration of Victorhy

Recruiting
2
60
Europe
TTB gel (dose 1), Victorhy, TTB gel (dose 2), Placebo
Dryox Health
Palmar Hyperhidrosis
06/24
12/24
MISC-SA/T, NCT06150313: Efficacy of the Mediational Intervention for Sensitizing Caregivers for Teachers and Self-Administered Versions

Recruiting
N/A
105
Europe
Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T), MISC for Trainers adapted for groups of Teachers, MISC-T, Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA), MISC-SA, Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU), MISC-R, TAU
Universitat Autonoma de Barcelona, Ministerio de Economía y Competitividad, Spain
Randomized Controlled Trial
01/25
02/25
COPERNICAN, NCT06353594: Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

Recruiting
N/A
1272
Europe
Primary PCI
Jorge Sanz Sanchez
ST Elevation Myocardial Infarction
09/26
09/35
NAGOMI COMPLEX, NCT05705973: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Active, not recruiting
N/A
3000
Europe, RoW
Ultimaster Nagomi™
Terumo Europe N.V.
Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
04/26
04/27
Sánchez, Emiliano Rodríguez
No trials found
Marcos, Manuel A Gomez
No trials found

Download Options